ABCs of ADCs: From PK to PD
Predictive bioanalytical strategies for the development of Antibody-Drug Conjugates (ADCs)
ADCs often fail because the drug gets to the right tissue, but misses its target. It’s not enough to just seek the concentration of your ADC in the tissue, you need to know its exact location to predict efficacy and move your development program forward with confidence. In this webinar, renowned scientists and industry thought leaders Troy Voelker and Corinne Ramos outline a holistic bioanalytical strategy for your ADC, incorporating traditional bioanalysis with spatial bioanalysis to reveal decision-making data about how your ADC engages with the complex microenvironment.
- Antibody payload concentration
- Conjugated antibody concentration
- Free payload concentration
- Spatial distribution
- Target engagement
- Toxicity
Meet CyTOF: Simultaneous Inflammatory Response Monitoring & Cell Population Characterization
Say goodbye to PBMC processing, cold-chain shipping, and multiple assays, and experience the power of a single assay which combines cellular phenotyping directly with the level of activation.
Inflammation plays a critical role in numerous disease processes, including autoimmune disorders, infectious diseases, and immune-related adverse effects in immunotherapy. The ability to accurately assess inflammation is critical for understanding disease mechanisms, monitoring treatment efficacy, and identifying novel therapeutic targets. Traditional cytokine assays often lack the cellular context necessary for fully understanding immune activation and regulation. Inflammatory responses are shaped by intricate cytokine networks and immune cell interactions, which demand a more integrated, high-resolution analytical approach to provide meaningful insights.
Through the development of a proprietary next-generation inflammatory response assay that analyzes 46 markers off the shelf, Aliri can bridge this gap by simultaneously measuring cytokines and immune cell phenotypes, delivering a multi-dimension multi-dimensional dataset to enhance translational research and clinical decision-making.
Audience Takeaways
- How CyTOF works
- Advantages of CyTOF over Flow Cytometry and kit-based LBAs
- Case Study of Aliri’s proprietary Inflammatory Response Assay in Action
On-Demand Webinar: Whole-Body Pharmacokinetics - A new and powerful label-free method to de-risk early-stage drug development
Understanding drug pharmacokinetics at the tissue level, beyond systemic exposure investigation obtained by plasma bioanalysis, is crucial for developing safe and efficient drugs. Although Quantitative Whole-Body Autoradiography (QWBA) has been used for decades in the pharmaceutical industry, its cost and lack of molecular specificity make it unsuitable for early evaluation of drug distribution and metabolites.
Join Aliri Lab Director, Mathieu Gaudin, Ph.D. and customer, Hervé Giorgi Ph.D., Non-clinical Development Director at Genfit, to explore how Mass Spectrometry Imaging of whole-body mice offers an effective experimental setting for comprehensive characterization of drug pharmacokinetics at an early stage, facilitating better and faster drug candidate selection.
Key Takeaways:
- Overview of Whole-Body Pharmacokinetics (PK) and its benefits
- How this new label-free method enables decision-making by providing insights into efficacy at the site of action, anticipating potential safety concerns, and supporting better clinical candidate selection
- A customer’s perspective on the implementation of this approach in their drug development strategy
Revolutionizing Bioanalysis: Harnessing AI for Enhanced Precision, Insights, and Efficiency
Does AI have a place in bioanalysis? We say YES!
In this session, tenured biomarker expert, Corinne Ramos, Phd, R&D Director at Aliri Bioanalysis, and Stephanie Papas-Farmer, PhD, President and Founder of BioData Solutions, share an overview of the state of AI in the drug development landscape, and real, data-backed bioanalytical applications for this powerful tool. Join us to explore how the power of AI in conjunction with genomic, proteomic, and metabolomic analyses can help predict the effectiveness of immunotherapies at an early stage in the drug development process, well before traditional methods would allow.
Watch the full-length recording below and reach out to learn how Aliri can enhance your drug development program and help you predict the effectiveness of immunotherapies earlier.